Krzysztof Brzozka
Overview
Explore the profile of Krzysztof Brzozka including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
2316
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gogola D, Novak Ratajczak S, Gabor-Worwa E, Kowal-Chwast A, Gaud N, Latacz G, et al.
J Pharm Biomed Anal
. 2025 Jan;
255():116665.
PMID: 39793369
Accurate determination of plasma protein binding (PPB) is crucial in understanding the pharmacokinetics and pharmacodynamics of drugs, particularly for highly bound compounds where traditional methods may fall short. In this...
2.
Zicari S, Merlino G, Paoli A, Fiascarelli A, Tunici P, Bisignano D, et al.
J Cell Mol Med
. 2024 Dec;
28(23):e70235.
PMID: 39653657
MEN1703 is a first-in-class, oral, Type I dual PIM/FMS-like tyrosine kinase 3 inhibitor (FLT3i) investigated in a Phase I/II DIAMOND-01 trial in patients with acute myeloid leukaemia (AML). Gilteritinib is...
3.
Gaud N, Gogola D, Kowal-Chwast A, Gabor-Worwa E, Littlewood P, Brzozka K, et al.
Drug Metab Pharmacokinet
. 2024 Aug;
57:101023.
PMID: 39088906
Rosiglitazone is an activator of nuclear peroxisome proliferator-activated (PPAR) receptor gamma used in the treatment of type 2 diabetes mellitus. The elimination of rosiglitazone occurs mainly via metabolism, with major...
4.
Gabor-Worwa E, Kowal-Chwast A, Gaud N, Gogola D, Littlewood P, Smoluch M, et al.
Eur J Drug Metab Pharmacokinet
. 2024 Apr;
49(3):393-403.
PMID: 38642299
Background And Objective: The prediction of pharmacokinetic parameters for drugs metabolised by cytochrome P450 enzymes has been the subject of active research for many years, while the application of in...
5.
Zhan Y, Guo J, Yang W, Goncalves C, Rzymski T, Dreas A, et al.
J Clin Invest
. 2024 Apr;
134(8).
PMID: 38618965
No abstract available.
6.
Kowal-Chwast A, Gabor-Worwa E, Gaud N, Gogola D, Piatek A, Zarebski A, et al.
Pharmacol Rep
. 2024 Mar;
76(2):400-415.
PMID: 38530582
Background: In predictions about hepatic clearance (CL), a number of studies explored the role of albumin and transporters in drug uptake by liver cells, challenging the traditional free-drug theory. It...
7.
Szydlowski M, Garbicz F, Jablonska E, Gorniak P, Komar D, Pyrzynska B, et al.
Cancer Res
. 2021 Oct;
81(23):6029-6043.
PMID: 34625423
The family of PIM serine/threonine kinases includes three highly conserved oncogenes, and , which regulate multiple prosurvival pathways and cooperate with other oncogenes such as . Recent genomic CRISPR-Cas9 screens...
8.
Dziedzic K, Wegrzyn P, Galezowski M, Bonkowska M, Grycuk K, Satala G, et al.
Int Immunopharmacol
. 2021 Apr;
96:107645.
PMID: 33894488
Immunosuppression is one of the main mechanisms facilitating tumor expansion. It may be driven by immune checkpoint protein expression, anti-inflammatory cytokine secretion or enhanced metabolic enzyme production, leading to the...
9.
Dreas A, Kucwaj-Brysz K, Pyziak K, Kulesza U, Wincza E, Fabritius C, et al.
Eur J Med Chem
. 2020 Dec;
213:113057.
PMID: 33303237
The mitogen-activated protein kinase (MAPK)-interacting kinases 1 and 2 (MNKs 1/2) and their downstream target eIF4E, play a role in oncogenic transformation, progression and metastasis. These results provided rationale for...
10.
Harrison D, Boutard N, Brzozka K, Bugaj M, Chmielewski S, Cierpich A, et al.
Bioorg Med Chem Lett
. 2020 Sep;
30(23):127560.
PMID: 32956781
The NLRP3 inflammasome is a component of the innate immune system involved in the production of proinflammatory cytokines. Aberrant activation by a wide range of exogenous and endogenous signals can...